Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 11
2004 12
2005 12
2006 23
2007 24
2008 29
2009 37
2010 38
2011 46
2012 40
2013 69
2014 121
2015 263
2016 503
2017 859
2018 1185
2019 1498
2020 1502
2021 1362
2022 733
2023 519
2024 322

Text availability

Article attribute

Article type

Publication date

Search Results

8,066 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms Controlling PD-L1 Expression in Cancer.
Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Cha JH, et al. Mol Cell. 2019 Nov 7;76(3):359-370. doi: 10.1016/j.molcel.2019.09.030. Epub 2019 Oct 24. Mol Cell. 2019. PMID: 31668929 Free PMC article. Review.
Various types of cancers express high levels of PD-L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity. ...Therefore, furthering our understanding of the regulatory mechanisms of PD-L1 can bring substantial benefits to patients with cancer by improving the …
Various types of cancers express high levels of PD-L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity. ...Therefore, furthe …
PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, Shi J, Hou Y. Gou Q, et al. Cell Death Dis. 2020 Nov 6;11(11):955. doi: 10.1038/s41419-020-03140-2. Cell Death Dis. 2020. PMID: 33159034 Free PMC article. Review.
T cell plays a critical role in killing cancer cells while the cancer cell exhibits immune escape by the expression of PD-L1. ...In this review, we have discussed the interaction of PD-L1 degradation with cancer immunotherapy....
T cell plays a critical role in killing cancer cells while the cancer cell exhibits immune escape by the expression of PD-L1. …
Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics.
Olalekan S, Xie B, Back R, Eckart H, Basu A. Olalekan S, et al. Cell Rep. 2021 May 25;35(8):109165. doi: 10.1016/j.celrep.2021.109165. Cell Rep. 2021. PMID: 34038734 Free article.
Understanding the cellular composition of the tumor microenvironment and the interactions of the cells is essential to the development of successful immunotherapies in cancer. We perform single-cell RNA sequencing (scRNA-seq) of 9,885 cells isolated from the omentum in 6 p …
Understanding the cellular composition of the tumor microenvironment and the interactions of the cells is essential to the development of su …
WNT signaling and cancer stemness.
Katoh M, Katoh M. Katoh M, et al. Essays Biochem. 2022 Sep 16;66(4):319-331. doi: 10.1042/EBC20220016. Essays Biochem. 2022. PMID: 35837811 Free PMC article.
Cancer stemness, defined as the self-renewal and tumor-initiation potential of cancer stem cells (CSCs), is a cancer biology property featuring activation of CSC signaling networks. ...Noncanonical WNT signaling supports maintenance of slowly cycling, quiesce …
Cancer stemness, defined as the self-renewal and tumor-initiation potential of cancer stem cells (CSCs), is a cancer bi …
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Yi M, et al. Mol Cancer. 2022 Jan 21;21(1):28. doi: 10.1186/s12943-021-01489-2. Mol Cancer. 2022. PMID: 35062949 Free PMC article. Review.
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten alpha-PD-1 (nivolumab, pembrolizumab, cemiplimab, sint …
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune respo …
A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy.
Alexander PG, McMillan DC, Park JH. Alexander PG, et al. Crit Rev Oncol Hematol. 2021 Jan;157:103147. doi: 10.1016/j.critrevonc.2020.103147. Epub 2020 Nov 19. Crit Rev Oncol Hematol. 2021. PMID: 33278675 Free article. Review.
BACKGROUND: PD-1 checkpoint inhibitors are novel therapeutic agents in colorectal cancer (CRC). Immunohistochemical staining for CD274 assessment is standardised in upper GI cancer, but not in CRC. ...As a marker of response to anti-PD-1 therapy, CD274 …
BACKGROUND: PD-1 checkpoint inhibitors are novel therapeutic agents in colorectal cancer (CRC). Immunohistochemical staining for C …
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Ohaegbulam KC, et al. Trends Mol Med. 2015 Jan;21(1):24-33. doi: 10.1016/j.molmed.2014.10.009. Epub 2014 Oct 30. Trends Mol Med. 2015. PMID: 25440090 Free PMC article. Review.
Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy …
Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in so …
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. Dermani FK, et al. J Cell Physiol. 2019 Feb;234(2):1313-1325. doi: 10.1002/jcp.27172. Epub 2018 Sep 7. J Cell Physiol. 2019. PMID: 30191996 Review.
Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. ...
Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cell …
PD-L1 status in breast cancer: Current view and perspectives.
Vranic S, Cyprian FS, Gatalica Z, Palazzo J. Vranic S, et al. Semin Cancer Biol. 2021 Jul;72:146-154. doi: 10.1016/j.semcancer.2019.12.003. Epub 2019 Dec 26. Semin Cancer Biol. 2021. PMID: 31883913 Review.
Breast cancer was traditionally not considered a particularly immunogenic tumor. ...These cancers have been shown to express molecules identified as targets for immunotherapy. ...
Breast cancer was traditionally not considered a particularly immunogenic tumor. ...These cancers have been shown to express m …
Overcoming T cell exhaustion in infection and cancer.
Pauken KE, Wherry EJ. Pauken KE, et al. Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18. Trends Immunol. 2015. PMID: 25797516 Free PMC article. Review.
Inhibitors of the Programmed Cell Death 1: Programmed Cell Death 1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell exhaustion, have been recently shown to be effective for treatment of different cancers. However, clinical responses are mixed, highlighting the …
Inhibitors of the Programmed Cell Death 1: Programmed Cell Death 1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell exhaustion, …
8,066 results